Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2000 1
2001 2
2002 5
2003 1
2004 1
2005 3
2006 4
2007 1
2008 1
2009 2
2011 2
2012 1
2013 1
2017 1
2018 1
2022 3
2023 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial.
Chéret A, Bauer R, Meiffrédy V, Lopez P, Ajana F, Lacombe K, Morlat P, Lascoux C, Reynes J, Calin R, Abel S, Goujard C, Rouzioux C, Avettand-Fenoel V, Meyer L. Chéret A, et al. Among authors: meiffredy v. J Antimicrob Chemother. 2022 Aug 25;77(9):2506-2515. doi: 10.1093/jac/dkac207. J Antimicrob Chemother. 2022. PMID: 35762503 Clinical Trial.
HIV-1-RNA and total HIV-1-DNA loads in the genital compartment in men receiving dolutegravir- versus darunavir-based combined ART (cART) regimens during primary HIV infection.
Mariaggi AA, Bauer R, Charre C, Gardiennet E, Meiffredy V, Ajana F, Lacombe K, Pialoux G, Cua E, Rouzioux C, Meyer L, Cheret A, Avettand-Fenoel V. Mariaggi AA, et al. Among authors: meiffredy v. J Antimicrob Chemother. 2022 Feb 23;77(3):735-739. doi: 10.1093/jac/dkab427. J Antimicrob Chemother. 2022. PMID: 35195692
Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients.
Colin de Verdiere N, Durier C, Samri A, Meiffredy V, Launay O, Matheron S, Mercier-Delarue S, Even S, Aboulker JP, Molina JM, Autran B, Simon F; ANRS EP46 NOVAA Group. Colin de Verdiere N, et al. Among authors: meiffredy v. AIDS. 2018 Oct 23;32(16):2291-2299. doi: 10.1097/QAD.0000000000001963. AIDS. 2018. PMID: 30096071
The build-up of stock of stable integrated proviruses overtime explains the difficulty in reducing HIV-1 DNA levels when treatment is initiated at the chronic stage of the infection.
Mchantaf G, Cheret A, Melard A, Essat A, Gardiennet E, Bauer R, Charre C, Meiffredy V, Piroth L, Goujard C, Meyer L, Avettand-Fenoel V. Mchantaf G, et al. Among authors: meiffredy v. J Virus Erad. 2023 Dec 9;9(4):100357. doi: 10.1016/j.jve.2023.100357. eCollection 2023 Dec. J Virus Erad. 2023. PMID: 38188640 Free PMC article.
Screening test for neutralizing antibodies against yellow fever virus, based on a flavivirus pseudotype.
Mercier-Delarue S, Durier C, Colin de Verdière N, Poveda JD, Meiffrédy V, Fernandez Garcia MD, Lastère S, Césaire R, Manuggera JC, Molina JM, Amara A, Simon F. Mercier-Delarue S, et al. Among authors: meiffredy v. PLoS One. 2017 May 31;12(5):e0177882. doi: 10.1371/journal.pone.0177882. eCollection 2017. PLoS One. 2017. PMID: 28562615 Free PMC article.
Effect of two injections of non-adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial.
Le Corre N, Thibault F, Pouteil Noble C, Meiffrédy V, Daoud S, Cahen R, Charreau I, Bottigioli D, Dollinger C, Aboulker JP, Autran B, Morelon E, Barrou B. Le Corre N, et al. Among authors: meiffredy v. Vaccine. 2012 Dec 14;30(52):7522-8. doi: 10.1016/j.vaccine.2012.10.047. Epub 2012 Oct 25. Vaccine. 2012. PMID: 23103195 Clinical Trial.
Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial.
INITIO Trial International Co-ordinating Committee; Yeni P, Cooper DA, Aboulker JP, Babiker AG, Carey D, Darbyshire JH, Floridia M, Girard PM, Goodall RL, Hooker MH, Mijch A, Meiffredy V, Salzberger B. INITIO Trial International Co-ordinating Committee, et al. Among authors: meiffredy v. Lancet. 2006 Jul 22;368(9532):287-98. doi: 10.1016/S0140-6736(06)69074-0. Lancet. 2006. PMID: 16860698 Clinical Trial.
31 results